Accounting: Should Not We Think Differently, but LogicallyEssay Preview: Accounting: Should Not We Think Differently, but LogicallyReport this essaySelect a public limited company from KSE quotations and pick up its annual reports for last consecutive 10 years. You will notice the following:That the number of pages of the annual reports in your hands over last 10 years has been doubled. This is regardless of the fact that the production and business volume might had been cut down to one half. The past trend of direct proportion between company profits / losses and annual report lookup is now no longer exists and you could not even guess a company’s performance by gazing the cover page of annual report!
The Company:
M.S.I. & J.D. Salekha
M.S.I. & D.M. Salekha is the world’s largest manufacturer of the finest-performing medical and biological chemicals and medical devices.
Its motto is: “It’s Your Fight, You Don’t Have to Be There”‑ it has more than 400 subsidiaries and 15 global stores, all at under $200 million each, and its worldwide headquarters, Tokyo.
M.S.I. is well recognized by its brands, clients, employees and suppliers:
A.L.T., H.M.D., L.B.M., H.E., L.D.M., and V.L.R.
H.E. includes a dedicated unit of 50,000+ employees.
L.D., H.M.D, and V.L.R are the leading medical device manufacturers.
In a recent research on our customers, we discovered the following.
The companies that make up our customers:
One of the largest pharmaceutical companies in the world, one of the nation’s most respected research institutions and among the top 5 most expensive pharmacist departments in the world.
Founded in 1975 by the founders of Pimax and other medical breakthroughs, M.S.I. makes the highest number of products in the world, making worldwide sales the biggest pharmaceutical company today, and the highest percentage of their total revenues coming from pharma.
This is a leading U.S. manufacturer of generic and other biologic drugs.
Rising pharmaceutical profits are the result of lower global corporate tax rates which affect us.
Pimax Corporation is the largest pharmaceutical company in the world, with more than $500 billion in revenues and over 10,000 patents.
In 1997, the U.S. Federal Trade Commission approved M.S.I.’s second, third, and sixth largest patent monopolies for medical devices and devices of various types and brands. These monopolies increased at least 150% from 2000 to 2011 and now allow for the largest expansion in world’s market in pharmaceuticals of this generation.
Pimax and other generic and other biologic drugs will increase in price if they will also have better patented design. If their profits start to increase more heavily, we will take a much stronger stance against them, as a global pharmaceutical company, than we could when the federal government backed those monopolies. More than $90 billion will be spent next year to reduce the regulatory requirements imposed on U.S. pharmaceutical companies.
In 1991, M.S.I. acquired a leading subsidiary, M. S.I. Holding
The Company:
M.S.I. & J.D. Salekha
M.S.I. & D.M. Salekha is the world’s largest manufacturer of the finest-performing medical and biological chemicals and medical devices.
Its motto is: “It’s Your Fight, You Don’t Have to Be There”‑ it has more than 400 subsidiaries and 15 global stores, all at under $200 million each, and its worldwide headquarters, Tokyo.
M.S.I. is well recognized by its brands, clients, employees and suppliers:
A.L.T., H.M.D., L.B.M., H.E., L.D.M., and V.L.R.
H.E. includes a dedicated unit of 50,000+ employees.
L.D., H.M.D, and V.L.R are the leading medical device manufacturers.
In a recent research on our customers, we discovered the following.
The companies that make up our customers:
One of the largest pharmaceutical companies in the world, one of the nation’s most respected research institutions and among the top 5 most expensive pharmacist departments in the world.
Founded in 1975 by the founders of Pimax and other medical breakthroughs, M.S.I. makes the highest number of products in the world, making worldwide sales the biggest pharmaceutical company today, and the highest percentage of their total revenues coming from pharma.
This is a leading U.S. manufacturer of generic and other biologic drugs.
Rising pharmaceutical profits are the result of lower global corporate tax rates which affect us.
Pimax Corporation is the largest pharmaceutical company in the world, with more than $500 billion in revenues and over 10,000 patents.
In 1997, the U.S. Federal Trade Commission approved M.S.I.’s second, third, and sixth largest patent monopolies for medical devices and devices of various types and brands. These monopolies increased at least 150% from 2000 to 2011 and now allow for the largest expansion in world’s market in pharmaceuticals of this generation.
Pimax and other generic and other biologic drugs will increase in price if they will also have better patented design. If their profits start to increase more heavily, we will take a much stronger stance against them, as a global pharmaceutical company, than we could when the federal government backed those monopolies. More than $90 billion will be spent next year to reduce the regulatory requirements imposed on U.S. pharmaceutical companies.
In 1991, M.S.I. acquired a leading subsidiary, M. S.I. Holding
The Company:
M.S.I. & J.D. Salekha
M.S.I. & D.M. Salekha is the world’s largest manufacturer of the finest-performing medical and biological chemicals and medical devices.
Its motto is: “It’s Your Fight, You Don’t Have to Be There”‑ it has more than 400 subsidiaries and 15 global stores, all at under $200 million each, and its worldwide headquarters, Tokyo.
M.S.I. is well recognized by its brands, clients, employees and suppliers:
A.L.T., H.M.D., L.B.M., H.E., L.D.M., and V.L.R.
H.E. includes a dedicated unit of 50,000+ employees.
L.D., H.M.D, and V.L.R are the leading medical device manufacturers.
In a recent research on our customers, we discovered the following.
The companies that make up our customers:
One of the largest pharmaceutical companies in the world, one of the nation’s most respected research institutions and among the top 5 most expensive pharmacist departments in the world.
Founded in 1975 by the founders of Pimax and other medical breakthroughs, M.S.I. makes the highest number of products in the world, making worldwide sales the biggest pharmaceutical company today, and the highest percentage of their total revenues coming from pharma.
This is a leading U.S. manufacturer of generic and other biologic drugs.
Rising pharmaceutical profits are the result of lower global corporate tax rates which affect us.
Pimax Corporation is the largest pharmaceutical company in the world, with more than $500 billion in revenues and over 10,000 patents.
In 1997, the U.S. Federal Trade Commission approved M.S.I.’s second, third, and sixth largest patent monopolies for medical devices and devices of various types and brands. These monopolies increased at least 150% from 2000 to 2011 and now allow for the largest expansion in world’s market in pharmaceuticals of this generation.
Pimax and other generic and other biologic drugs will increase in price if they will also have better patented design. If their profits start to increase more heavily, we will take a much stronger stance against them, as a global pharmaceutical company, than we could when the federal government backed those monopolies. More than $90 billion will be spent next year to reduce the regulatory requirements imposed on U.S. pharmaceutical companies.
In 1991, M.S.I. acquired a leading subsidiary, M. S.I. Holding
That the reports have become more and more colorful rather can be said to have incorporated “the multimedia”. Benefits of automation and IT developments are being enjoyed by everyone and annual reports are no exception!
That the financial information is preceded and followed by colorful photographs. The nature of these photographs differs from company to company and the regression curve may depict that in future these photos may look like those on some fashion magazine! This would add to the ultimate demand of annual reports and we shall have to incorporate another “user” group in our accounting studies.
That one has to turn plenty of pages before one can reach to some purposeful informative page. How ever, this has definitely added to the income of printers and to some extent, of the auditors as well.
That more and more technical, difficult and complex terminology is being used in the disclosures to the audited accounts which make the common reader understand that accounting profession is really “something” and that this something is really “something difficult to grasp”.
I have no concrete statistics to support whatever I am writing next, but I assume you would agree with the same if you think and evaluate unbiased.That the number of readers has inversely reduced to the number of pages over last ten years. That is, when pages are more than doubled, readers are more than halved.
That those still evaluating annual reports information have confined themselves to only a few limited number of pages, which to them are relevant and useful.
That despite so much detailed and incorporating such a variety of financial information, the specific object oriented user groups also do not take the annual reports as conclusive. Make a loan application to a bank and submit your company’s annual report and wait for the loan to be disbursed in your company’s account! Logically, the documents required to be submitted in such a scenario should be reduced over time as the annual audited accounts now carry variety of information along with them in annual report. But the opposite is the case. The number of documents